Professor Margot Umpleby
Biography
Professor Umpleby obtained her first degree in Biochemistry from the University of Cambridge and her PhD from the University of London. She held various academic appointments between 1982 and 2005 at UMDS subsequently Kings College London. She was appointed Professor of Human Metabolism at Surrey University in 2005.
She is an international expert on the use of stable isotopes for the study of human metabolism. Her research aims to understand the mechanisms that lead to insulin resistance and abnormalities in fatty acid and lipoprotein metabolism in diabetes, obesity, metabolic syndrome and non alcoholic fatty liver disease. She works in partnership with clinicians at the Royal Surrey County Hospital. She also works closely with the Pharmaceutical Industry in the investigation of new treatments.
Her expertise has led to collaborations worldwide and 150 peer reviewed publications. She has received over £3.5m in research funding in the last 10 years from the BBSRC, BHF, Diabetes UK, European Foundation for the Study of Diabetes, MRC, NIHR and the Pharmaceutical industry.
Research interests
Her research strategy focuses on:
- understanding the underlying mechanisms that lead to metabolic abnormalities in diabetes, obesity, metabolic syndrome and non alcoholic fatty liver disease.
- the translation of this understanding into effective treatment.
She is uniquely able to conduct this research strategy due to her expertise in the use of stable isotope techniques, and their measurement by mass spectrometry which can determine in vivo the rates of synthesis, disposal and conversion of metabolites in the body.
Current research projects
Are gut hormone changes why the long-limb gastric bypass is more effective than the standard-limb gastric bypass in improving type 2 diabetes mellitus? (funded by NIHR. PI Steve Bloom, Imperial College London)
Effects of SGLT2 inhibitor on Glucose Flux, Lipolysis and Ketogenesis during insulin withdrawal in People with Absolute or Relative Insulin Deficiency (funded by Diabetes UK. PI Roselle Herring, Royal Surrey County Hospital, Guildford)
The South London Diabetes and Ethnicity Phenotyping Study (funded by Diabetes UK. PI Louise Goff Kings College London)
The Effect of a SGLT2 inhibitor on Glucose flux, Lipolysis and Exercise in type 2 Diabetes (SINGLED) (funded by Astra Zeneca. PI Roselle Herring, Royal Surrey County Hospital, Guildford)
Areas of specialism
My qualifications
Affiliations and memberships
Research
Research interests
Her research strategy focuses on:
- understanding the underlying mechanisms that lead to metabolic abnormalities in diabetes, obesity, metabolic syndrome and non alcoholic fatty liver disease.
- the translation of this understanding into effective treatment.
She is uniquely able to conduct this research strategy due to her expertise in the use of stable isotope techniques, and their measurement by mass spectrometry which can determine in vivo the rates of synthesis, disposal and conversion of metabolites in the body.
Current research projects
Are gut hormone changes why the long-limb gastric bypass is more effective than the standard-limb gastric bypass in improving type 2 diabetes mellitus? (funded by NIHR. PI Steve Bloom, Imperial College London)
Effects of SGLT2 inhibitor on Glucose Flux, Lipolysis and Ketogenesis during insulin withdrawal in People with Absolute or Relative Insulin Deficiency (funded by Diabetes UK. PI Roselle Herring, Royal Surrey County Hospital, Guildford)
The South London Diabetes and Ethnicity Phenotyping Study (funded by Diabetes UK. PI Louise Goff Kings College London)
The Effect of a SGLT2 inhibitor on Glucose flux, Lipolysis and Exercise in type 2 Diabetes (SINGLED) (funded by Astra Zeneca. PI Roselle Herring, Royal Surrey County Hospital, Guildford)
My publications
Publications
Whyte MB, Jackson NC, Shojaee-Moradie F, Treacher DF, Beale RJ, Jones RH, Umpleby AM. (2009)The Metabolic Effects of Intensive Insulin Therapy in Critically Ill Patients. Am J Physiol (In Press)
Smeeton F, Shojaee Moradie F, Jones RH, Westergaard L, Haahr H, Umpleby AM, Russell-Jones DL. (2009) Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. Diabetologia. 52:2317-23
Brackenridge AL, Jackson N, Jefferson W, Stolinski M, Shojaee-Moradie F, Hovorka R, Umpleby AM, Russell-Jones D (2009) Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with type 2 diabetes. Diabetic Medicine 26:532-9
Giannoulis MG, Jackson N, Shojaee-Moradie F, Nair KS, Sonksen PH, Martin F, Umpleby AM. (2008) The Effects of Growth Hormone and/or Testosterone on Whole Body Protein Kinetics and Skeletal Muscle Gene Expression in Healthy Elderly Men: A Randomized Controlled Trial. J Clin Endocrinol Metab. 93:3066-74
Shojaee-Moradie F, Baynes KCR, Pentecost C, Bell JD, Thomas EL, Jackson NC, Stolinski M, Whyte M, Lovell D, Bowes SB, Gibney J, Jones RH, Umpleby AM (2007) Exercise training reduces fatty acid availability and improves insulin sensitivity of glucose metabolism. Diabetologia 50:404-413.
Healy ML, Gibney J, Pentecost C, Croos P, Russell-Jones DL, Sönksen PH, Umpleby AM (2006) Effects of High Dose Growth Hormone on Glucose and Glycerol Metabolism at Rest and During Exercise in Endurance-Trained Athletes. J Clin Endocrinol Metab 91: 320-7.
Das S, Shahmanesh M, Stolinski M, Shojaee-Moradie F, Jefferson W, NC Jackson Cobbald M, Nightingale P, Umpleby AM. (2006) In treatment naïve and antiretroviral treated HIV infected subjects reduced plasma adiponectin is associated with a reduced fractional catabolic rate of VLDL, IDL and LDL apolipoprotein B-100. Diabetologia 49:538-42
Brackenridge A, Pearson ER, Shojaee-Moradie F, Hattersley AT, Russell-Jones DL, Umpleby AM (2006) Contrasting insulin sensitivity of endogenous glucose production rate in subjects with Hepatocyte Nuclear Factor-1β and Hepatocyte Nuclear Factor-1α mutations Diabetes 55: 405-411